CA2892021A1 - Engineered secreted proteins and methods - Google Patents

Engineered secreted proteins and methods Download PDF

Info

Publication number
CA2892021A1
CA2892021A1 CA2892021A CA2892021A CA2892021A1 CA 2892021 A1 CA2892021 A1 CA 2892021A1 CA 2892021 A CA2892021 A CA 2892021A CA 2892021 A CA2892021 A CA 2892021A CA 2892021 A1 CA2892021 A1 CA 2892021A1
Authority
CA
Canada
Prior art keywords
amino acid
protein
amino acids
nutritive
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2892021A
Other languages
English (en)
French (fr)
Inventor
Subhayu Basu
Katherine G. Gora
Ying-Ja CHEN
David M. Young
Nathaniel W. SILVER
Michael HAMILL
David A. Berry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axcella Health Inc
Original Assignee
Pronutria Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronutria Inc filed Critical Pronutria Inc
Publication of CA2892021A1 publication Critical patent/CA2892021A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/18Peptides; Protein hydrolysates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30Dietetic or nutritional methods, e.g. for losing weight
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2408Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411Amylases
    • C12N9/2428Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2434Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2434Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2445Beta-glucosidase (3.2.1.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477Hemicellulases not provided in a preceding group
    • C12N9/248Xylanases
    • C12N9/2482Endo-1,4-beta-xylanase (3.2.1.8)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2892021A 2012-11-20 2013-11-20 Engineered secreted proteins and methods Abandoned CA2892021A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728427P 2012-11-20 2012-11-20
US61/728,427 2012-11-20
PCT/US2013/071091 WO2014081884A1 (en) 2012-11-20 2013-11-20 Engineered secreted proteins and methods

Publications (1)

Publication Number Publication Date
CA2892021A1 true CA2892021A1 (en) 2014-05-30

Family

ID=50776536

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2892021A Abandoned CA2892021A1 (en) 2012-11-20 2013-11-20 Engineered secreted proteins and methods

Country Status (7)

Country Link
US (1) US20150307562A1 (enExample)
EP (1) EP2922416A4 (enExample)
JP (1) JP2016500250A (enExample)
CN (1) CN104936466A (enExample)
CA (1) CA2892021A1 (enExample)
HK (1) HK1214739A1 (enExample)
WO (1) WO2014081884A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3217807A4 (en) * 2014-11-11 2018-09-12 Clara Foods Co. Methods and compositions for egg white protein production

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015029580A2 (pt) * 2013-05-31 2017-09-19 Dsm Ip Assets Bv Microrganismo recombinante, processo para a preparação de um diterpeno ou diterpeno glicosilado, diterpeno ou diterpeno glicosilado, gêneros alimentícios, alimentos para animais ou bebidas e método para converter um primeiro diterpeno glicosilado em um segundo diterpeno glicosilado
CN105916981A (zh) 2013-07-29 2016-08-31 丹尼斯科美国公司 变体酶
EP3048904A2 (en) * 2013-09-25 2016-08-03 Pronutria Biosciences, Inc. Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof
GB201401699D0 (en) * 2014-01-31 2014-03-19 Dupont Nutrition Biosci Aps Protein
CN103881994B (zh) * 2014-04-14 2020-03-27 中国农业科学院生物技术研究所 一种具有高转糖苷活性的β-半乳糖苷酶突变体及其制备方法和应用
FR3022558B1 (fr) 2014-06-20 2019-01-25 Proteus Variants d'exoglucanases a activite amelioree et leurs utilisations
ES2896401T3 (es) * 2014-09-22 2022-02-24 Tanea Medical Ab Proteínas recombinantes exentas de Phe para su uso en el tratamiento de la fenilcetonuria
CN107135653A (zh) * 2014-10-01 2017-09-05 安迅生物制药公司 大肠杆菌素变体
DK3234143T5 (da) 2014-12-19 2024-10-14 Novozymes As Sammensætninger omfattende polypeptider med xylanaseaktivitet og polypeptider med arabinofuranosidaseaktivitet
GB201501565D0 (en) * 2015-01-30 2015-03-18 Dupont Nutrition Biosci Aps Method
WO2016149482A2 (en) * 2015-03-17 2016-09-22 Vanderbilt University Cs21 and lnga protein vaccines
DK3313193T3 (da) * 2015-06-26 2021-06-07 Novozymes As Fremgangsmåde til fremstilling af en kaffeekstrakt
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
WO2017142080A1 (ja) 2016-02-18 2017-08-24 天野エンザイム株式会社 腸内菌叢改善剤
WO2017202997A1 (en) * 2016-05-24 2017-11-30 Novozymes A/S Compositions comprising polypeptides having galactanase activity and polypeptides having beta-galactosidase activity
EP3462904B1 (en) * 2016-05-24 2024-12-18 Novozymes A/S Gastric stable polypeptides having alpha-galactosidase activity and polynucleotides encoding same
WO2017202966A1 (en) 2016-05-24 2017-11-30 Novozymes A/S Polypeptides having alpha-galactosidase activity and polynucleotides encoding same
US11273455B2 (en) 2016-06-27 2022-03-15 Novozymes A/S Method of dewatering post fermentation fluids
DK3481948T5 (da) * 2016-07-08 2024-09-02 Novozymes As Xylanasevarianter og polynukleotider, der koder for dem
JP6845244B2 (ja) * 2016-07-19 2021-03-17 サントリーホールディングス株式会社 モグロールまたはモグロール配糖体の生産方法
PT3290436T (pt) 2016-09-01 2019-08-30 Metax Inst Fuer Diaetetik Gmbh Proteína livre de fenilalanina para o tratamento de pku
EA201891926A1 (ru) * 2017-02-03 2019-04-30 Киверди, Инк. Микроорганизмы и искусственные экосистемы для производства белка, продуктов питания и полезных побочных продуктов из субстратов c1
EP3592429A1 (en) * 2017-03-06 2020-01-15 DuPont Nutrition Biosciences ApS Novel fungal fucosidases and their use in preventing and/or treating a pathogenic infection in an animal
EP3840582A4 (en) * 2018-08-21 2022-08-03 Clara Foods Co. MODIFICATION OF PROTEIN GLYCOSYLATION IN MICROORGANISMS
EP3877519B1 (en) 2018-11-09 2026-03-11 Ginkgo Bioworks, Inc. Biosynthesis of mogrosides
MX2021011361A (es) * 2019-03-19 2021-10-13 Bayer Cropscience Lp Proteinas de fusion, bacterias recombinantes y fragmentos de exosporios para la salud de las plantas.
SI3997118T1 (sl) 2019-07-11 2025-06-30 Clara Foods Co. Sestavek napitka, ki obsega rekombinantni ovomukoidni protein
US12096784B2 (en) 2019-07-11 2024-09-24 Clara Foods Co. Protein compositions and consumable products thereof
US10927360B1 (en) 2019-08-07 2021-02-23 Clara Foods Co. Compositions comprising digestive enzymes
PY2055454A (es) 2019-09-16 2022-03-31 Novozymes As Polipéptidos que poseen actividad de beta-glucanasa y polinucleótidos que los codifican
EP3892290A1 (en) * 2020-04-08 2021-10-13 NUMAFERM GmbH Variants of hlya and uses thereof
US12612436B2 (en) 2020-03-18 2026-04-28 Numaferm Gmbh Variants of hlya and uses thereof
WO2021207679A1 (en) * 2020-04-10 2021-10-14 Liberty Biosecurity, Llc Polypeptide compositions and uses thereof
CA3198703A1 (en) * 2020-11-13 2022-05-19 Timothy GEISTLINGER Methods and compositions for producing recombinant components for use in food and other products
US20240117331A1 (en) * 2021-02-10 2024-04-11 Novozymes A/S Polypeptides having pectinase activity, polynucleotides encoding same, and uses thereof
MX2023011028A (es) * 2021-03-25 2023-09-27 Bio Cat Inc Mezclas de proteasas micoticas y usos de las mismas.
CN114015678A (zh) * 2021-09-30 2022-02-08 中南民族大学 一种球形赖氨酸芽孢杆菌C3-41来源的氨肽酶Amp0279及其重组菌株和应用
MX2021014268A (es) * 2021-11-19 2022-02-16 Univ Mexico Nac Autonoma Proteina optimizada que comprende los aminoacidos esenciales para la nutricion humana.
US20230281444A1 (en) * 2022-03-04 2023-09-07 Cella Farms Inc Computational system and algorithm for selecting nutritional microorganisms based on in silico protein quality determination
KR20250005200A (ko) 2022-04-20 2025-01-09 노보자임스 에이/에스 유리 지방산을 제조하는 방법
WO2023215798A1 (en) * 2022-05-04 2023-11-09 Locus Biosciences, Inc. Phage compositions for escherichia comprising crispr-cas systems and methods of use thereof
US20250311734A1 (en) 2022-05-14 2025-10-09 Novozymes A/S Compositions and Methods for Preventing, Treating, Suppressing and/or Eliminatting Phytopathogenic Infestations and Infections
CN115160420B (zh) * 2022-06-24 2023-06-02 西南大学 盔形毕赤酵母scp类分泌蛋白及其应用
WO2024220717A1 (en) * 2023-04-20 2024-10-24 Ginkgo Bioworks, Inc. Biosynthesis of mogrosides
WO2025155915A1 (en) * 2024-01-17 2025-07-24 Anagram Therapeutics, Inc. Methods and compositions for treating congenital sucrase-isomaltase deficiency

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800726B1 (en) * 1996-11-01 2004-10-05 Pioneer Hi-Bred International, Inc. Proteins with increased levels of essential amino acids
AR017831A1 (es) * 1997-12-10 2001-10-24 Pioneer Hi Bred Int Metodo para alterar la composicion de aminoacidos de una proteina nativa de interes, proteina elaborada, y polinucleotido
US20060159724A1 (en) * 2000-08-08 2006-07-20 Bell Stacey J Nutritional supplement for the management of weight
BR0212530A (pt) * 2001-09-17 2005-04-12 Monsanto Technology Llc Proteìnas reforçadas e métodos para seu uso
US7273738B2 (en) * 2002-10-01 2007-09-25 Novozymes A/S Family GH-61 polypeptides
CN1557475A (zh) * 2004-02-04 2004-12-29 高春平 美容、减肥营养组合物
EP2327316B1 (en) * 2009-11-29 2016-11-16 Premier Nutrition Corporation Method of enhancing muscle protein synthesis
CA2786001A1 (en) * 2009-12-31 2011-07-07 Pioneer Hi-Bred International, Inc. Engineering plant resistance to diseases caused by pathogens
WO2012128260A1 (ja) * 2011-03-24 2012-09-27 旭硝子株式会社 シゾサッカロミセス属酵母の形質転換体、該形質転換体の製造方法、β-グルコシダーゼの製造方法、およびセルロースの分解方法
WO2013148329A1 (en) * 2012-03-26 2013-10-03 Pronutria, Inc. Charged nutritive proteins and methods

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3217807A4 (en) * 2014-11-11 2018-09-12 Clara Foods Co. Methods and compositions for egg white protein production
US20240083977A1 (en) * 2014-11-11 2024-03-14 Clara Foods Co. Methods and compositions for egg white protein production

Also Published As

Publication number Publication date
HK1214739A1 (zh) 2016-09-30
JP2016500250A (ja) 2016-01-12
WO2014081884A9 (en) 2015-05-21
US20150307562A1 (en) 2015-10-29
WO2014081884A1 (en) 2014-05-30
EP2922416A4 (en) 2016-07-20
EP2922416A1 (en) 2015-09-30
CN104936466A (zh) 2015-09-23

Similar Documents

Publication Publication Date Title
US20240150406A1 (en) Charged Nutritive Proteins and Methods
US20150307562A1 (en) Engineered secreted proteins and methods
US9944681B2 (en) Nutritive fragments, proteins and methods
US9605040B2 (en) Nutritive proteins and methods
US20150126441A1 (en) Nutritive Fragments and Proteins with Low or No Phenylalanine and Methods
US20170327548A1 (en) Charged Nutritive Fragments, Proteins and Methods
HK40037265A (en) Nutritive fragments, proteins and methods

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160809

FZDE Discontinued

Effective date: 20181023